ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.00
0.72%
US Tech 100
19,734.40
0.00%
S&P 500
5,815.03
0.61%
US Dollar vs CAD
1.37798
-0.02%
Bitcoin
64,065.90
1.93%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Quince Therapeutics Inc (QNCX) Share Price

Quince Therapeutics Inc

Quince Therapeutics Inc (QNCX)

NASDAQ
0.694
0.00
(0.00%)
Closed October 14 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.694
Bid
0.6577
Ask
0.79
Volume
-
0.00 Day's Range 0.00
0.5116 52 Week Range 1.4301
Market Cap
30.034M
Previous Close
0.694
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
164,554
Shares Outstanding
43,276,606
Dividend Yield
-
PE Ratio
-2.69
Earnings Per Share (EPS)
-0.73
Revenue
-
Net Profit
-31.39M

About Quince Therapeutics Inc

Quince Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on advancing precision therapeutics designed to precisely deliver small molecules, peptides, and large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety con... Quince Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on advancing precision therapeutics designed to precisely deliver small molecules, peptides, and large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety concerns. Quince Therapeutics serves customers in the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
quincetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Quince Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker QNCX. The last closing price for Quince Therapeutics was US$0.69. Over the last year, Quince Therapeutics shares have traded in a share price range of US$ 0.5116 to US$ 1.4301.

Quince Therapeutics currently has 43,276,606 shares outstanding. The market capitalization of Quince Therapeutics is US$30.03 million. Quince Therapeutics has a price to earnings ratio (PE ratio) of -2.69.

Ask ADVFN Intelligence (AI)

QNCX Latest News

More News

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

September 03 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

August 21 2024
Edgar (US Regulatory)

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age...

August 15 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 13 2024
Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a...

August 13 2024
Business Wire

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease...

June 25 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.066-8.684210526320.760.8180.69341910.72320065CS
4-0.036-4.931506849320.730.86990.69657720.78071795CS
12-0.046-6.216216216220.740.86990.51161645540.62447041CS
26-0.256-26.94736842110.951.120.51161320610.72174616CS
52-0.296-29.8989898990.991.43010.51161042200.8642598CS
156-75.716-99.091741918676.4181.55990.51166013136.59533632CS
260-23.056-97.077894736823.75121.980.511643658914.64096934CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.05
(0.00%)
0
AACGATA Creativity Global
US$ 0.9404
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.05
(0.00%)
0
AACGATA Creativity Global
US$ 0.9404
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 11.79
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 64.67
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.05
(0.00%)
0
AACGATA Creativity Global
US$ 0.9404
(0.00%)
0

QNCX Discussion

View Posts
Viewmont Viewmont 2 months ago
$QNCX Nice! https://finance.yahoo.com/news/quince-therapeutics-announces-lancet-neurology-110000014.html
👍️0
INFINITI INFINITI 2 months ago
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Source
👍️0
Monksdream Monksdream 2 months ago
QNCX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
QNCX
👍️0
Monksdream Monksdream 8 months ago
QNCX under $2
👍️0
AKATITUS AKATITUS 10 months ago
Slow climber
👍️0
Monksdream Monksdream 1 year ago
QNCX under $2
👍️0
AKATITUS AKATITUS 1 year ago
Bought some 1.10s
See what happens
👍️0
knrorrel knrorrel 1 year ago
News https://www.stocktitan.net/news/QNCX/quince-therapeutics-to-acquire-ery-del-sp-a-and-its-phase-3-asset-02yx0yj60e08.html
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX - Up 10% Pre-Market/ Current Price $1.75
To Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX- Up 26% Pre-Market/ Current Price $1.24
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics
Increases offer to $1.80 per share + CVR to receive 85% of the future net proceeds of Quince as part of the Lighthouse Pharmaceuticals transaction
👍️0
alchemytrader alchemytrader 2 years ago
Happens. Dirty diluting CEOs
👍️0
Backstabbed Backstabbed 2 years ago
Sorry to hear that
👍️0
alchemytrader alchemytrader 2 years ago
not true. i lost my ass trying to swing PSFE HLBZ FUV. took a terrible loss after finally fiving up. Had i held on i would have lost 90-99% of my money.
👍️0
Backstabbed Backstabbed 2 years ago
all about patience. they all run eventually
👍️0
alchemytrader alchemytrader 2 years ago
congrats
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - added today!
👍️0
Backstabbed Backstabbed 2 years ago
nice. very low PPS here after it hit a high of $1.75 in PM last week
👍️0
Sirpeter Sirpeter 2 years ago
Hi buddy...added it to watch
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - News out!!! Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
👍️0
tw0122 tw0122 2 years ago
$1.33 running again
👍️0
saj saj 2 years ago
Mid 1.3's nice pop on news
👍️0
makinezmoney makinezmoney 2 years ago
$QNCX: Decent bounce move here..... now 0.74


2 days now back to back....................... it was receding since Summer last ear and now finally going


On WATCH


GO $QNCX
👍️0
cash4 cash4 2 years ago
https://www.otcmarkets.com/filing/html?id=15980132&guid=AKk-kW7ZRh7-B3h
👍️0

Your Recent History

NASDAQ
QNCX
Quince Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved